Role of the transforming growth factor-b1 (TGF-b1) gene polymorphisms located at codons 10 and 25 in the genetic predisposition to type 2 diabetes (T2D) and in diabetic nephropathy (DN) in Egyptian patients was investigated. A case control study was done for 99 unrelated Egyptian patients with T2D (50 DN 2 and 49 DN
Introduction
Type 2 diabetes (T2D) is a common, chronic, complex disorder of rapidly growing global importance. It accounts for .95% of diabetes worldwide and is characterized by concomitant defects in insulin secretion (from the b-cells in the pancreatic islets) and insulin action (in fat, muscle, liver, and elsewhere), the latter being typically associated with obesity [1] . It is affected by multiple genetic and environmental factors. Extensive efforts have been made to identification of the disease-affecting genes to get better understanding of the disease pathogenesis, find new targets for clinical therapy and allow prediction of the disease [2] .
The maximal capacity of cytokine production in individuals has a major genetic component [3] . A potential mechanism was described involving polymorphisms within the coding regions or signal sequences of cytokine genes [4] . These genetic polymorphisms were shown to affect the overall expression and secretion of cytokines both in vitro and sporadically in vivo systems. Associations among polymorphisms in cytokine genes and inflammation, allograft rejection, autoimmune, and infectious diseases have been reported [4] [5] [6] [7] . In diabetes mellitus, cytokine gene polymorphism may reflect or control the severity and progression of various immunological phenomena associated with the disease [8] .
Transforming growth factor-b (TGF-b) belongs to a family of multifunctional growth factors, which have profound regulatory effects on many developmental and physiological processes [9] . The human TGF-b1 gene is located on chromosome 19q13.1-13.3 [10] , and more than 10 polymorphic loci are presently known, distributed in exons, introns, and the 5 0 -flanking region [11] . The hotspots focus on the single nucleotide polymorphisms (SNPs) of codons 10 and 25 [12] . The polymorphisms at codons 10 and 25 may be associated with higher or lower TGF-b1 synthesis in vitro [13] . Increases or decreases in the production of TGF-b1 have been linked to numerous diseases including atherosclerosis, and fibrotic diseases of the kidney, liver, and lung [14] . SNP at TGF-b1 has been linked with an increased likelihood of having diabetic nephropathy (DN). It has been proposed that the TGF-b1 gene participates in the development of renal hypertrophy and in the accumulation of extracellular matrix in diabetes [15] .
DN is a major long-term complication of both T1D and T2D and is the leading cause of end-stage renal disease in many parts of the world [16] . Factors known to be associated with development and progression of DN, including hyperglycemia, increased intraglomerular pressure, mesangial cell stretch, activation of renin-angiotensin system, and hypertension, have all been shown to induce TGF-b1 production in the kidney or in cultured mesangial or tubular cells [17] .
Thus, this case control preliminary study was designed to investigate the possible role of the functional polymorphism of TGF-b1 (codon 10 and codon 25) gene in the progression of T2D into DN in Egyptian population in order to elucidate the association of these variants with the clinical and laboratory findings suggesting that SNPs in TGF-b1 may play an important role in the genetic predisposition either in T2D or progression to DN.
Materials and Methods
Patients and healthy controls This study was conducted on 99 unrelated Egyptian patients including 16 males and 83 females with T2D recruited consecutively from Internal Medicine Outpatients Clinic (Mansoura University Hospital, Mansoura, Egypt). T2D was defined by the criteria of American Diabetes Association 2010 [18] . The mean age of these patients was 47.67 + 8.34 years at disease onset, and the mean duration of diabetes was 9.13 + 5.24 years. Informed consent was obtained from all the study subjects. All investigations were done in accordance with the Health and Human Ethical Clearance Committee guidelines for Clinical Researches in Menofiya University. Local ethics committee approved the study protocol.
Blood samples were drawn for measuring fasting and postprandial blood glucose, cholesterol and triglycerides, albumin, and creatinine (Biomerieux, Paris, France). Glycated hemoglobin (HbA1c) was measured by an ion-exchange chromatographic method (Teco Diagnostica, Anaheim, USA) with reference range from 6.6% to 8.6%.
A total of 99 Egyptian patients with T2D were categorized into 50 patients without diabetic nephropathy (DN 2 ) and 49 patients with diabetic nephropathy (DN þ ). DN was determined on the basis of questionnaire, clinical features, and laboratory data. Spot urine samples were used for the detection of microalbuminuria by a quantitative nephelometric method (Turbox; Orion Diagnostica, Espoo, Finland) with reference range ,20 mg/l. The diagnosis of microalbuminuria was defined if at least two out of three samples are positive over a period of 3-6 months [18] .
Another 98 unrelated healthy age-and sex-matched nondiabetic, non-hypertensive subjects living in the same geographical area and have the same ethnic origin as patients were recruited as healthy controls.
TGF-b1 codons 10 and 25 gene polymorphism by amplification refractory mutation system technique DNA was extracted from whole venous blood using the EZNA blood DNA extraction kit (Omega Bio-Tek, Qiagene, USA). Typing of TGF-b codons 10 and 25 gene polymorphism was performed with amplification refractory mutation system reaction similar to that first described by Perrey et al. [19] .
Sequence of primers (Biolegia, BV Nijmegen, the Netherlands) used were codon-10 (T869C)-C allele primer: 0 -TCACGGATTTCTGTTGTGTTTC-3 0 . Reaction volume was 25 ml: 5 ml DNA at 100 ng/ml, 12.5 ml DreamTaq Green mater mix (Fermentas, St Leon-Rot, Germany), 0.5 ml of each primer (25 pmol/ml), and 5.5 ml H 2 O. Reaction conditions were carried out in thermal cycler PTC-100 (Bio-Rad, Hercules, USA), 958C for 1 min followed by 10 cycles of 958C for 15 s, 658C for 50 s, and 728C for 40 s, then 20 cycles of 958C for 20 s, 568C for 50 s, and 728C for 50 s. The amplified PCR products were analyzed by 2% agarose gel. PCR products were at 241, 233, and 429 bp for codon 10, codon 25, and internal control, respectively.
Statistical analysis
Deviations from Hardy-Weinberg were tested using an exact test (available at http://ihg.gsf.de/cgi-bin/hw/hwa1/pI). All of the statistical analysis was performed on a personal computer using the Statistical Package for Social Science (SPSS) version 13 (LEAD Technology Inc., Charlotte, USA). Data are presented as the mean + SD. Comparisons among different groups of patients were performed by one-way analysis of variance. Tukey's post hoc test was used. The x 2 test was used to compare the frequency of variables in different groups, and Fisher's exact test was used if a cell was below expected and odds ratio (OR) and 95% confidence interval (CI) were calculated as determined by the program software. P value that remained below 0.05 after correction for the number of variables (P corrected, Pc) was considered significant (Bonferroni correction). The haplotype frequencies were estimated with linkage disequilibrium coefficient, D, using the Haploview program (available at http://www.broad.mit.edu/mpg/haploview).
Results
Demographic and biochemical characteristics of T2D patients T2D patients were categorized into 49 DN þ patients and 50 DN 2 patients, thus 49.5% of T2D were DN patients. Demographic and biochemical data of different groups of DN 2 and DN þ patients were summarized in Table 1 . For DN þ , 47% had macroalbuminuria and 53% had microalbuminuria. DN 2 patients were confirmed by the absence of microalbuminuria and serum creatinine ,132.18 mM.
Both groups had similar gender distribution, duration of diabetes, blood pressure, on using insulin, fasting and 2 h postprandial blood sugar, HbA1c, and serum cholesterol. DN 2 patients are generally older, statistically significant difference (P , 0.001) was found between DN 2 and DN þ .
Negative correlation was recorded between the age of the patients and the progress of DN (r ¼ 20.562, P , 0.001). DN þ patients had statistically significant (P , 0.001) higher body mass index. Positive correlation was recorded between the body mass index of the patients and the progress of the disease (r ¼ 0.459, P , 0.001). Compared with DN 2 patients, higher statistically significance (P , 0.001) prevalence of DN þ patients (100% vs. 62%) treated with angiotensin-converting enzyme inhibitor. DN þ patients had a statistically significant (P , 0.001) increase in serum creatinine and serum triglyceride, lower serum albumin than DN 2 patients. Positive correlation between serum triglyceride (r ¼ 0.558, P , 0.001), serum creatinine (r ¼ 0.515, P , 0.001), and formation of DN was demonstrated. In contrast, negative correlation was recorded between serum albumin (r ¼ 20.773, P , 0.001) and disease progress. The influence of the grades of HbA1c control (good, moderate, and bad) on the development of DN was reported. The moderate and bad grades of HbA1c control were associated with DN (P , 0.001). Table 2 . A statistically significant difference was detected between the control group and Egyptian patients with T2D in the frequencies of the TGF-b1 codon 10 (P , 0.001).
On the other hand, statistically insignificant difference was reported between controls and T2D patients in the frequencies of TGF-b1 codon 25.
As shown in Table 2 , T2D patients had increased frequency of TGF-b1 CC and TC genotypes (TT, TC, CC ¼ 39.4%, 50.5%, 10.1%, respectively) vs. controls (TT, CT, CC ¼ 69.4%, 27.6%, 3%, respectively). TC genotype distribution was statistically significant (Pc , 0.001) in T2D patients as compared with normal controls. In contrast, elevation in TT genotype frequency was statistically significant (Pc , 0.001) in normal controls. The TC/CC vs. TT genotype had OR of 3.49 (95% CI ¼ 1.94-6.29) under a dominant model (Pc , 0.001) indicating to association of T/C SNP (either homo or hetero) with T2D. The frequencies of C alleles were also higher among T2D patients than controls (35.4% vs. 16.8%, Pc , 0.001). In codon 25, although an increase in GC genotype in patients than controls was demonstrated, it is statistically insignificant.
We analyzed the linkage disequilibrium (LD) pattern between the 869 T/C and 915 G/C SNP. The two polymorphisms did not show significant LD, with a D 0 value of 0.067 and an r 2 value of 0.002. In accordance with the results of the analysis of the individual markers, the haplotype analysis also showed a significant association of TGF-b1 codon 10 polymorphism with T2D ( Table 2) . Increase in TG and TC haplotypes frequency in control with respect to patients (P , 0.05 and P , 0.001, respectively). Thus, the haplotypes TG and TC may be protective for the disease. There is an excess of haplotypes CC and CG in T2D patients with respect to the control (P , 0.01 and P , 0.05, respectively) indicating that the haplotypes CC and CG may be susceptible to T2D.
TGF-b1 polymorphism analysis in T2D patients with and without nephropathy The distribution of the genotypes and alleles in T2D patients with (DN þ ) and without (DN 2 ) diabetic nephropathy is shown in Table 3 . The values predicted by Table 2 Distributions of TGF-b1 codon 10 (T869C) and codon 25 (G915C) genotypes and allele frequencies in T2D patients and controls Association between grades of diabetic control and TGF-b1 codons 10/25 genotypes in T2D patients To demonstrate if the TGF-b1 codons 10/25 genotypes have any relation to the control of diabetes, association between grades of diabetic control and change in genotypes of TGF-b1 codons 10 and 25 was performed ( Table 4) . In codon 10, most of T2D patients with TT genotype had moderate grade of control (P , 0.05) where the bad grade was associated with the TC (P , 0.01). The same results were obtained for TGF-b1 codons 25 (P , 0.05 for GC genotypes with bad grade).
Discussion
There is mounting evidence that the ability of an individual to produce high or low levels of TGF-b1 may be genetically predetermined [14, 20] . Altered TGF-b1 expression due to polymorphisms affects a wide variety of normal cellular and disease processes such as T cell activation and proliferation, tumor progression, and asthma [21] . Polymorphisms at codons 10 and 25 may be associated with higher or lower TGF-b1 synthesis in vitro [13, 14] . Polymorphisms at codons 10 and 25 have been linked with several diseases including autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus, infectious, and fibrotic diseases [15] . Few studies were investigating the dual effects of TGF-b1 codons 10/25 gene polymorphisms in the onset of T2D and DN complications.
The results of the present study showed increased frequency of TGF-b1 CC and TC genotypes compared with Table 3 Distribution of TGF-b1 codon 10 (T869C) and codon 25 (G915C) genotypes and alleles in T2D patients with and without DN controls. In contrast, elevation in TT genotype frequency was statistically significant in normal controls. The frequencies of C alleles were also higher among T2D patients than controls. In codon 25, statistically insignificant increase in GC genotype in patients than controls was demonstrated. Buraczynska et al. [22] and Wong et al. [23] studied TGF-b1 codon 10 polymorphism on Polish and Chinese populations, respectively. They reported different distribution of alleles, and genotypes compared with those in Egyptians. The difference between two studies could be returned to the difference in different population genetic background. Because of the variation in cytokine allele frequency in different populations, it is not surprising that our results of TGF-b1 genetic polymorphisms associated with T2D are conflicting in different ethnic groups. However, the small sample size in the present study is a limiting factor to have conclusive results.
Nowadays, growing evidence indicates that activation of the innate immune system and the development of a systemic low-grade chronic inflammation are closely involved in the pathogenesis of T2D. The innate immune system modulates the effects of many factors including genes, ethnicity, fetal programming, nutrition, and age on the later development of metabolic sequelae associated with insulin resistance [24] . TGF-b1 is an anti-inflammatory immune mediator because it is a critical regulator of the immune system with mainly immunosuppressive effects [25] . In addition to effects on T cells, TGF-b1 inhibits or reverses the activation of macrophages by interfering with signaling via toll-like receptor-dependent pathways and downregulating central effecter mechanisms of the innate immunity such as lipopolysaccharide-induced production of proinflammatory cytokines, reactive oxygen species, and reactive nitrogen species [26] .
Herder et al. [27] found that elevated serum concentrations of TGF-b1 were associated with incident of T2D and elevated IL-1Ra. Although IL-1Ra is an anti-inflammatory cytokine that improves metabolic control in patients with T2D [28] , this study found that elevated, not decreased, levels of IL-1Ra preceded the development of T2D. This new finding underlines that the immune activation during the development of T2D is complex and includes both proand anti-inflammatory mediators [27] .
Herder et al. [27] suggested another explanation for elevated TGF-b1 that it could also play a proinflammatory role in the development of T2D. The action of TGF-b1 depends on the microenvironment (different leukocyte subsets and cytokines), and TGF-b1 can also positively regulate immune responses [29] . In the presence of IL-6, TGF-b1 supports the differentiation of T-helper 17 (Th17) cells that are activated in many proinflammatory conditions. Interestingly, IL-6 levels were also increased before the onset of T2D in this study [30] . Activated Th17 cells release proinflammatory cytokines such as IL-17 that has been reported to stimulate nitric oxide-mediated b-cell toxicity in a mouse model [31] .
The previously described inflammatory and antiinflammatory activities of TGF-b1 and its signaling pathway is often inactivated by mutation or altered expression of its component during pancreatic disease progression such as T2D [32] . SNPs in codons 10 and 25 of TGF-b1 alter the amino acid sequence (Leu10Pro and Arg25Pro, respectively) and also affect TGF-b1 levels [13, 33] . TGF-b1 Pro10 (C) allele secretes almost twice as much as Leu10 (T) allele [33] . TGF-b1 over-expression is one of the most constant molecular features of pathological tissue fibrosis leading to organ failure [34] . Depending on these studies, it is expected that the documented polymorphism in codon 10 in the present work (as shown from increasing percentage of TC and CC genotypes) may be resulted in elevation in TGF-b1 secretion level and consequently to increased incidence of T2D. Therefore, it is expected from this study that T allele is protective while C allele is susceptible for occurrence of T2D.
While the importance of metabolic and blood pressure control in the pathogenesis of DN is fully recognized [35] , the role of genetic factor is still poorly understood [23] . One of the major growth factors involved in extracellular matrix accumulation in fibrotic disorders, including DN, is TGF-b [34] , which represents important regulator of tissue fibrosis that plays a pivotal role in the pathogenesis of DN [36] . Involvement of TGF-b1 in DN has been indicated by prior findings that protein and mRNA production of TGF-b1 were significantly enhanced in the renal tissues of patients with DN [37, 38] . TGF-b expression is especially increased in mesangial cells of diabetic glomeruli [39, 40] , but increased TGF-b expression in glomerular endothelial cells has been also reported. Inhibition of TGF-b results in prevention of fibrosis under experimental diabetic conditions. Elevated concentration of TGF-b1 could induce renal hypertrophy and promote excessive accumulation of extracellular matrix [41] . These pathological changes contribute to the initiation and progression of DN. In the present work, analyzing the frequency of TGF-b1 codons 10 and 25 alleles and genotypes in T2D patients in the presence or absence of DN revealed that statistically insignificant associations were found except for the TC genotype. This increase in frequency of TC genotype in patients with DN indicated that it could be a risk factor for DN þ .
The association between the TGF-b1 T869C polymorphism and DN risk showed contradictory results. While, significant associations were reported in Chinese [23] , Caucasians Polish [22] , and Mexicans [42] , insignificant associations were reported in Asian Indians [43] and in Japanese [44] . Although the present study has no CC genotypes among selected DN patients, the significant increase in TC genotype in DN þ patients is in accordance with the meta-analysis study of Jia et al. [45] on TGF-b1 T869C (codon 10) polymorphism. They confirmed that the C allele and the C allele-containing genotypes (TC and CC) were associated with increased risk of DN compared with T allele, and TT genotype in all studied population (especially Asians). Although the exact mechanism underlying the effect of TGF-b1 T869C polymorphism on DN susceptibility was not well known, multiple studies conducted in various populations suggested that the T869C polymorphism was associated with altered TGF-b1 protein expression [45] .
In this study, analyzing the frequency of TGF-b1 codon 25 alleles and genotypes in T2D patients in the presence or absence of DN revealed that statistically insignificant associations were found. These results are in contrast to the data presented by Valladares-Salgado et al. [42] , who reported a positive association between GCþCC genotypes of TGF-b1 G915C and DN in Mexicans. This difference may be returned to the ethnic difference between Egyptians and Mexicans. With the absence of any previous study on Egyptian population, a repetition with larger population is mandatory.
Elevated concentration of TGF-b1 could induce renal hypertrophy and promote excessive accumulation of extracellular matrix [41] , and exactly these pathological changes contribute to the initiation and progression of DN. Evidences from in vivo and in vitro studies have indicated that increased concentration of glucose could stimulate TGF-b1 expression both in cultured renal cells and in the kidney [39, 46] , which suggested that TGF-b1 might play an important role in the etiology of DN both in T1D and T2D [45] .
Association between grades of diabetic control and change in genotypes of TGF-b1 codons 10 and 25 was performed to demonstrate if the TGF-b1 codons 10/25 genotypes had any relation in control of diabetes. In codon 10, most of T2D patients with TT genotype had moderate grade of control where the bad grade was associated with the TC. The same results were obtained for TGF-b1 codon 25. The mean level of HbA1c is correlated with the loss of renal function [47] . The pathophysiological basis for elevated the urinary albumin entails binding of glucose to proteins in excessive protein glycosylation with build up glycosylated end products. This is encoded by transcription of the gene for TGF-b, which is stimulated by hyperglycemia, resulting in upregulation of glucose transport-1 in the mesangial cells [48, 49] . This lead to deposition of advanced glycation end products on the glomerulus that is recognized by the receptor of advanced glycation end products selectively on the glomerular epithelial cells. These resulted in the thickness effect of glomerular capillaries: accumulation of mesangial basement membrane. Deposition of fibrin and increase vascular permeability, these abnormalities permit leakage of low-molecular-weight albumin [49] .
In conclusion, our data stressed the importance of TGF-b1 gene polymorphism in developing T2D and its role in progression of the disease toward nephropathy occurrence. This preliminary study indicated that TGF-b1 T869C (codon 10) C allele, and C allele-containing genotypes may be susceptible, and the T allele/TT genotype may be protective factors for T2D and DN þ complications. G915C (codon 25) gene polymorphism has no implications on incidence of T2D or DN complications. However, one of the shortcomings of this study is its rather small sample size; therefore, the results should be confirmed in a larger series, as well as in patients of different ethnic origins. Thus, based on these findings, a further analysis of other immune response gene(s) polymorphisms in large series is required to elucidate the consequence of gene variants in T2D and diabetic complications.
